These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 10481412)

  • 1. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Sato K; Ogasawara K; Akaki T; Tomioka H
    Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
    Sato K; Tomioka H
    Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
    Sato K; Tomioka H; Akaki T; Kawahara S
    Int J Antimicrob Agents; 2000 Sep; 16(1):25-9. PubMed ID: 11185410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Invasion and intracellular growth of Mycobacterium tuberculosis and Mycobacterium avium complex adapted to intramacrophagic environment within macrophages and type II alveolar epithelial cells].
    Sato K; Akaki T; Shimizu T; Sano C; Ogasawara K; Tomioka H
    Kekkaku; 2001 Feb; 76(2):53-7. PubMed ID: 11260925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
    Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nontuberculous mycobacteriosis; the present status and in the future. Mechanisms of host resistance to Mycobacterium avium complex and Mycobacterium tuberculosis infection].
    Tomioka H; Sato K; Shimizu T; Akaki T
    Kekkaku; 1998 Feb; 73(2):71-6. PubMed ID: 9545699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
    Sato K; Tomioka H; Sano C; Shimizu T; Sano K; Ogasawara K; Cai S; Kamei T
    J Antimicrob Chemother; 2003 Aug; 52(2):199-203. PubMed ID: 12865388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
    Cai S; Sato K; Shimizu T; Yamabe S; Hiraki M; Sano C; Tomioka H
    J Antimicrob Chemother; 2006 Jan; 57(1):85-93. PubMed ID: 16303883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-Mycobacterium avium complex activities of KRM-1648, clarithromycin and levofloxacin in 7HSF medium at peak or average blood concentrations after their oral administration of clinical dosages].
    Sato K; Akaki T; Tomioka H
    Kekkaku; 1997 Jul; 72(7):449-53. PubMed ID: 9259129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
    Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.
    Tomioka H; Sato K; Sano C; Sano K; Shimizu T
    Antimicrob Agents Chemother; 2002 Feb; 46(2):519-21. PubMed ID: 11796367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
    Sato K; Akaki T; Tomioka H
    J Antimicrob Chemother; 1998 Jan; 41(1):77-83. PubMed ID: 9511040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells.
    Sato K; Tomioka H
    J Antimicrob Chemother; 1999 Mar; 43(3):351-7. PubMed ID: 10223590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with glycyrrhizin against Mycobacterium avium complex infection in mice].
    Shimizu T; Tomioka H; Sato K; Akaki T; Ogasawara K; Kawahara S
    Kekkaku; 1999 Aug; 74(8):617-21. PubMed ID: 10487030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice].
    Sato K; Shimizu T; Tomioka H; Kawahara S
    Kekkaku; 1998 Aug; 73(8):501-6. PubMed ID: 9780605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
    Mor N; Simon B; Heifets L
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.
    Inderlied CB; Barbara-Burnham L; Wu M; Young LS; Bermudez LE
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1838-43. PubMed ID: 7986017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.